Monocytosis as a Prognostic Factor in Idiopathic Pulmonary Fibrosis
DOI:
https://doi.org/10.70749/ijbr.v3i7.1803Keywords:
Idiopathic Pulmonary Fibrosis, Monocytosis, Prognostic Marker, Mortality, Biomarker, Interstitial Lung DiseaseAbstract
Objective: To determine increased monocyte, count (monocytosis) as a cellular biomarker for poor outcomes in idiopathic pulmonary fibrosis METHODS: A descriptive cross-sectional study was conducted at Allied Hospital-2, Faisalabad. A total of 305 patients aged 30–70 years with confirmed IPF were enrolled using non-probability consecutive sampling. Monocyte counts were classified into three groups: Group I (<0.60 × 10⁹/L), Group II (0.60–<0.95 × 10⁹/L), and Group III (≥0.95 × 10⁹/L). The primary outcome was in-hospital all-cause mortality. RESULTS: The mean age was 50.6 ± 12.2 years; 53.1% were female. Mortality was significantly higher in Group III (48.6%) compared to Group I (2.9%) and Group II (48.6%) (p = 0.017). Stratified analysis revealed consistent trends, with statistically significant associations in non-smokers (p = 0.048), non-diabetics (p = 0.035), non-MI patients (p = 0.020), and hypertensive patients (p = 0.041). Elevated monocyte count was a strong predictor of poor outcomes across subgroups. CONCLUSION: Elevated monocyte count, particularly ≥0.95 × 10⁹/L, is associated with increased in-hospital mortality in IPF. Given its accessibility and cost-effectiveness, monocyte count can be used as a prognostic tool for risk stratification and early clinical decision-making.
Downloads
References
1. Amaral AF, Colares PD, Kairalla RA. Idiopathic pulmonary fibrosis: current diagnosis and treatment. J Bras Pneumol. 2023;49: e20230085.
https://doi.org/10.36416/1806-3756/e20230085
2. Maher TM. Interstitial Lung Disease: A Review. JAMA 2024;331(19):1655–65. https://doi.org/10.1001/jama.2024.3669
3. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet 2022;400(10354):769-86. Epub 2022 Aug 11. PMID: 35964592.
https://doi.org/10.1016/S0140-6736(22)01052-2.
4. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Antoniou KM, Bissell BD, et al. Idiopathic Pulmonary Fibrosis (an Update) and progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/ JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9): e18-47.
https://doi.org/10.1164/rccm.202202-0399st
5. Zhang X, Ren Y, Xie B, Ye Q, Ban C, Zhang S, et al. Blood monocyte counts as a prognostic biomarker and predictor in Chinese patients with idiopathic pulmonary fibrosis. Front Med. 2022; 9: e955125.
https://doi.org/10.3389/fmed.2022.955125
6. Fraser E, Denney L, Antanaviciute A, Blirando K, Vuppusetty C, Zheng Y, et al. Multi-modal characterization of monocytes in idiopathic pulmonary fibrosis reveals a primed type I interferon immune phenotype. Frontiers Immunol. 2021; 12: e623430.
https://doi.org/10.3389/fimmu.2021.623430
7. Bernardinello N, Grisostomi G, Cocconcelli E, Castelli G, Petrarulo S, Biondini D, Saetta M, Spagnolo P, Balestro E. The clinical relevance of lymphocyte to monocyte ratio in patients with Idiopathic Pulmonary Fibrosis (IPF). Respir Med. 2022; 191: e106686.
https://doi.org/10.1016/j.rmed.2021.106686
8. Perrot CY, Karampitsakos T, Herazo-Maya JD. Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis. Am J Physiol Cell Physiol. 2023;325(4):1046-57.
https://doi.org/10.1152/ajpcell.00302.2023
9. Kreuter M, Lee JS, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, et al. Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care 2021; 204: 74–81.
https://doi.org/10.1164/rccm.202003-0669oc
10. Teoh AKY, Jo HE, Chambers DC, et al. Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registry. Eur Respir J 2020;55(5):1901855.
https://doi.org/10.1183/13993003.01855-2019.
11. Min B, Grant-Orser A, Johannson KA. Peripheral blood monocyte count and outcomes in patients with interstitial lung disease: a systematic review and meta-analysis. Eur Respir Rev 2023;32(169):230072.
https://doi.org/10.1183/16000617.0072-2023.
12. Scott MKD, Quinn K, Li Q, et al. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective cohort study. Lancet Digit Health 2021;3(3):e122–e131.
https://doi.org/10.1016/S2589-7500(21)00126-8
13. Hirata M, Hara Y, Fujii H, et al. ILD-GAP combined with the monocyte ratio could be a better prognostic prediction model than ILD-GAP in patients with interstitial lung diseases. BMC Pulm Med 2024;24(1):16.
https://doi.org/10.1186/s12890-023-02833-6.
14. Kim TH, Kim HJ, Song MJ, et al. Correlation of monocyte counts with clinical outcomes in idiopathic nonspecific interstitial pneumonia. Sci Rep 2023;13:2804.
https://doi.org/10.1038/s41598-023-28638-5.
15. Zhang X, Gao H, Zhang Z, et al. IPF-related new macrophage subpopulations and diagnostic biomarker identification–combine machine learning with single-cell analysis. Respir Res 2024;25:42.
https://doi.org/10.1186/s12931-024-02845-8
16. Zhou Y, Li X, Xiao W, et al. Monocyte signature predicts prognosis in idiopathic pulmonary fibrosis. Front Immunol. 2023;14:1308594. https://doi.org/10.3389/fimmu.2023.1308594.
17. Fernandez IE, Kass DJ. Do circulating monocytes promote and predict idiopathic pulmonary fibrosis progression? Am J Respir Crit Care Med. 2021;204(1):9–11.
https://doi.org/10.1164/rccm.202101-0207ED.
18. Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest 2021;131(2):e143226.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
